Literature DB >> 7297915

Circulating immune complexes in patients with fulminant hepatic failure.

J Canalese, R J Wyke, D Vergani, A L Eddleston, R Williams.   

Abstract

Circulating immune complexes were found in 15 of 16 patients with fulminant hepatic failure due to viral hepatitis and all of six patients who had had halothane anaesthesia; however, they were found in only five of 32 patients with paracetamol-induced hepatic necrosis. The levels of circulating immune complexes were not related to the severity of the clinical course, development of renal failure, final outcome, or severity of hypocomplementaemia. All the patients had depressed reticuloendothelial function as assessed by the clearance of 125I microaggregated albumin. These findings show that circulating immune complexes in fulminant hepatic failure are not simply a reflection of an immune response to liver antigens released as a result of the hepatic necrosis; nor are they a reflection of the failure of the reticuloendothelial system. This supports the view that circulating immune complexes are associated with immune mediated liver injury and may contribute to the process.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7297915      PMCID: PMC1419432          DOI: 10.1136/gut.22.10.845

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  15 in total

1.  Reticuloendothelial function in renal allograft recipients.

Authors:  G Drivas; P R Uldall; N Wardle
Journal:  Br Med J       Date:  1975-09-27

2.  Studies of the reticuloendothelial system (RES). I. Measurement of the phagocytic capacity of the RES in man and dog.

Authors:  M IIO; H N WAGNER; U SCHEFFEL; B JABBOUR
Journal:  J Clin Invest       Date:  1963-03       Impact factor: 14.808

3.  Relation of renal impairment and haemorrhagic diathesis to endotoxaemia in fulminant hepatic failure.

Authors:  S P Wilkinson; V Arroyo; B G Gazzard; H Moodie; R Williams
Journal:  Lancet       Date:  1974-03-30       Impact factor: 79.321

Review 4.  The management of fulminant hepatic failure.

Authors:  C Trey; C S Davidson
Journal:  Prog Liver Dis       Date:  1970

5.  Haemolytic diffusion plate assays for factors B and D of the alternative pathway of complement activation.

Authors:  A Martin; P J Lachmann; L Halbwachs; M J Hobart
Journal:  Immunochemistry       Date:  1976-04

6.  Hepatitis B antigen (HBSAg) and/or antibodies (anti-HBS and anti-HBC) in fulminant hepatitis: pathogenic and prognostic significance.

Authors:  C G Trepo; D Robert; J Motin; D Trepo; M Sepetjian; A M Prince
Journal:  Gut       Date:  1976-01       Impact factor: 23.059

7.  Detection of immune complexes in unheated sera by modified 125I-Clq binding test. Effect of heating on the binding of Clq by immune complexes and application of the test to systemic lupus erythematosus.

Authors:  R H Zubler; G Lange; P H Lambert; P A Miescher
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

8.  Frequency and type of renal and electrolyte disorders in fulminant hepatic failure.

Authors:  S P Wilkinson; L M Blendis; R Williams
Journal:  Br Med J       Date:  1974-02-02

9.  Studies on the mechanism of solubilization of immune precipitates by serum.

Authors:  J Czop; V Nussenzweig
Journal:  J Exp Med       Date:  1976-03-01       Impact factor: 14.307

10.  The morphology of virus-antibody interaction.

Authors:  J D Almeida; A P Waterson
Journal:  Adv Virus Res       Date:  1969       Impact factor: 9.937

View more
  5 in total

Review 1.  Halothane and liver damage.

Authors:  D Rosenak; A Halevy; R Orda
Journal:  Postgrad Med J       Date:  1989-03       Impact factor: 2.401

Review 2.  Halothane anaesthesia and liver damage.

Authors:  J Neuberger; R Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1984-10-27

Review 3.  Severe acute hepatitis A associated with acute pure red cell aplasia.

Authors:  S Tomida; Y Matsuzaki; M Nishi; T Ikegami; T Chiba; M Abei; N Tanaka; T Osuga; Y Sato; T Abe
Journal:  J Gastroenterol       Date:  1996-08       Impact factor: 7.527

4.  Serum stimulatory activity and polymorphonuclear leucocyte movement in patients with fulminant hepatic failure.

Authors:  R J Wyke; A G Yousif-Kadaru; I A Rajkovic; A L Eddleston; R Williams
Journal:  Clin Exp Immunol       Date:  1982-11       Impact factor: 4.330

5.  Serological markers in fulminant hepatitis B.

Authors:  A E Gimson; R S Tedder; Y S White; A L Eddleston; R Williams
Journal:  Gut       Date:  1983-07       Impact factor: 23.059

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.